NFE2L2 and age-related macular degeneration: Therefore, the development of novel antioxidant drugs targeting the activation of the Keap1/Nrf2/ARE antioxidant pathway is considered a promising approach to the treatment of AMD and other degenerative diseases involving a delicate intracellular oxidant–antioxidant imbalance.